Arrowhead Pharmaceuticals Deferred Revenue 2011-2026 | ARWR

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Arrowhead Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.4 M	-	866 K	74.1 M	111 M	19.3 M	77.8 M	600	5.27 M	2.57 M	103 K	103 K	103 K	37.5 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
111 M	600	22.6 M

Quarterly Deferred Revenue Arrowhead Pharmaceuticals

2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
23 M	-	-	-	-	-	866 K	16.9 M	29.8 M	66.3 M	74.1 M	-	97.9 M	109 M	111 M	151 M	111 M	6.74 M	19.3 M	19.3 M	19.3 M	54 M	77.8 M	77.8 M	77.8 M	125 M	600	943 K	1.56 M	1.88 M	5.27 M	5.27 M	5.27 M	25.6 M	2.57 M	2.57 M	2.57 M	109 K	103 K	103 K	103 K	109 K	103 K	103 K	103 K	109 K	103 K	103 K	103 K	109 K	37.5 K	37.5 K	37.5 K	101 K	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
151 M	600	27.6 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	227 K	-	-24.86 %	$ 820 K	USA
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	726 K	$ 2.75	-5.5 %	$ 155 M	China
ANI Pharmaceuticals ANIP	80 K	$ 81.6	-0.49 %	$ 1.58 B	USA
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Aytu BioScience AYTU	339 K	$ 2.63	1.74 %	$ 16.5 M	USA
Alterity Therapeutics Limited ATHE	33.3 K	$ 3.17	-2.76 %	$ 7.63 B	Australia
Aravive ARAV	4.41 M	-	-13.39 %	$ 1.45 M	USA
Biogen BIIB	55.7 M	$ 178.24	1.2 %	$ 26 B	USA
Brickell Biotech BBI	1.8 M	-	-5.38 %	$ 6.06 M	USA
Beam Therapeutics BEAM	109 M	$ 27.94	-4.61 %	$ 2.3 B	USA
Ascendis Pharma A/S ASND	363 K	$ 225.36	0.63 %	$ 5 B	Danmark
BioNTech SE BNTX	300 M	$ 114.18	-2.22 %	$ 27.2 B	Germany
CASI Pharmaceuticals CASI	2.35 M	$ 0.99	-0.01 %	$ 135 M	USA
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Catalyst Biosciences CBIO	39 K	$ 9.63	-5.08 %	$ 634 M	USA
Bellicum Pharmaceuticals BLCM	2.98 M	-	-9.72 %	$ 5.89 M	USA
Adaptimmune Therapeutics plc ADAP	29 M	-	-15.15 %	$ 60.3 M	Britain
Berkeley Lights BLI	9.09 M	-	-7.31 %	$ 87 M	USA
Can-Fite BioPharma Ltd. CANF	405 K	$ 4.05	-1.22 %	$ 8.81 B	Israel
AIkido Pharma AIKI	240 K	-	1.93 %	$ 17.4 M	USA
Cerus Corporation CERS	1.4 M	$ 2.32	-0.22 %	$ 428 M	USA
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	2.91 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	35.6 M	-	-	$ 2.17 B	USA
AlloVir ALVR	2.66 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	85.7 K	-	-11.43 %	$ 502 K	USA